PMID- 30110936
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20211204
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 8
DP  - 2018 Aug 14
TI  - Biological Aspects of mTOR in Leukemia.
LID - 10.3390/ijms19082396 [doi]
LID - 2396
AB  - The mammalian target of rapamycin (mTOR) is a central processor of intra- and 
      extracellular signals, regulating many fundamental cellular processes such as 
      metabolism, growth, proliferation, and survival. Strong evidences have indicated 
      that mTOR dysregulation is deeply implicated in leukemogenesis. This has led to 
      growing interest in the development of modulators of its activity for leukemia 
      treatment. This review intends to provide an outline of the principal biological 
      and molecular functions of mTOR. We summarize the current understanding of how 
      mTOR interacts with microRNAs, with components of cell metabolism, and with 
      controllers of apoptotic machinery. Lastly, from a clinical/translational 
      perspective, we recapitulate the therapeutic results in leukemia, obtained by 
      using mTOR inhibitors as single agents and in combination with other compounds.
FAU - Mirabilii, Simone
AU  - Mirabilii S
AD  - Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and 
      Psychology, Department of Clinic and Molecular Medicine, Sapienza University of 
      Rome, via Rovigo 1, 00161 Rome, Italy. simone.mirabilii@uniroma1.it.
FAU - Ricciardi, Maria Rosaria
AU  - Ricciardi MR
AD  - Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and 
      Psychology, Department of Clinic and Molecular Medicine, Sapienza University of 
      Rome, via Rovigo 1, 00161 Rome, Italy. mariarosaria.ricciardi@uniroma1.it.
FAU - Piedimonte, Monica
AU  - Piedimonte M
AD  - Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and 
      Psychology, Department of Clinic and Molecular Medicine, Sapienza University of 
      Rome, via Rovigo 1, 00161 Rome, Italy. monica.piedimonte@uniroma1.it.
FAU - Gianfelici, Valentina
AU  - Gianfelici V
AD  - Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and 
      Psychology, Department of Clinic and Molecular Medicine, Sapienza University of 
      Rome, via Rovigo 1, 00161 Rome, Italy. gianfelici@bce.uniroma1.it.
FAU - Bianchi, Maria Paola
AU  - Bianchi MP
AD  - Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and 
      Psychology, Department of Clinic and Molecular Medicine, Sapienza University of 
      Rome, via Rovigo 1, 00161 Rome, Italy. mariapaolabianchi82@gmail.com.
FAU - Tafuri, Agostino
AU  - Tafuri A
AD  - Laboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and 
      Psychology, Department of Clinic and Molecular Medicine, Sapienza University of 
      Rome, via Rovigo 1, 00161 Rome, Italy. agostino.tafuri@uniroma1.it.
AD  - Hematology, "Sant'Andrea" University Hospital, Sapienza University of Rome, via 
      di Grottarossa 1035, 00189 Rome, Italy. agostino.tafuri@uniroma1.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180814
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (RNA, Neoplasm)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Transformation, Neoplastic/*metabolism/pathology
MH  - Humans
MH  - Leukemia/drug therapy/*enzymology
MH  - MicroRNAs/metabolism
MH  - Neoplasm Proteins/antagonists & inhibitors/*metabolism
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - RNA, Neoplasm/metabolism
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
PMC - PMC6121663
OTO - NOTNLM
OT  - apoptosis
OT  - cell signaling
OT  - leukemia
OT  - mTOR inhibitors
OT  - metabolism
OT  - miRNA
COIS- The authors declare no conflict of interest.
EDAT- 2018/08/17 06:00
MHDA- 2018/11/15 06:00
PMCR- 2018/08/01
CRDT- 2018/08/17 06:00
PHST- 2018/07/17 00:00 [received]
PHST- 2018/08/07 00:00 [revised]
PHST- 2018/08/10 00:00 [accepted]
PHST- 2018/08/17 06:00 [entrez]
PHST- 2018/08/17 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/08/01 00:00 [pmc-release]
AID - ijms19082396 [pii]
AID - ijms-19-02396 [pii]
AID - 10.3390/ijms19082396 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Aug 14;19(8):2396. doi: 10.3390/ijms19082396.